Chartwell Investment Partners, LLC Castle Biosciences Inc Transaction History

Chartwell Investment Partners, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$16.0 - $45.99 $232,128 - $667,222	-14,508 Closed	0 $0
Q1 2022 Apr 26, 2022	BUY	$33.17 - $46.98 $20,134 - $28,516	607 Added 4.37%	14,508 $650,000
Q4 2021 Feb 15, 2022	SELL	$39.06 - $67.58 $9,569 - $16,557	-245 Reduced 1.73%	13,901 $595,000
Q2 2021 Jul 19, 2021	BUY	$50.07 - $76.78 $6,358 - $9,751	127 Added 0.91%	14,146 $1.04 Million
Q1 2021 May 03, 2021	SELL	$58.92 - $97.33 $366,718 - $605,781	-6,224 Reduced 30.75%	14,019 $960,000
Q4 2020 Feb 09, 2021	BUY	$43.6 - $73.05 $207,492 - $347,644	4,759 Added 30.73%	20,243 $1.36 Million
Q2 2020 Jul 29, 2020	SELL	$27.28 - $43.01 $154,022 - $242,834	-5,646 Reduced 26.72%	15,484 $584,000
Q1 2020 Apr 30, 2020	BUY	$23.08 - $35.53 $54,814 - $84,383	2,375 Added 12.66%	21,130 $630,000
Q4 2019 Jan 29, 2020	SELL	$15.74 - $35.04 $289,616 - $644,736	-18,400 Reduced 49.52%	18,755 $645,000
Q3 2019 Oct 29, 2019	BUY	$18.09 - $27.92 $672,133 - $1.04 Million	37,155 New	37,155 $672,000

210

26.6M

128K

35.4K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $677M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of Chartwell Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Chartwell Investment Partners, LLC with notifications on news.